NASHVILLE, Tenn., November 21, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX ...

NASHVILLE, Tenn., March 24, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has ...

Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022.

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutic ...

Harrow shares rose 9.3% to close at $26.66 during the session. Devon Energy shares gained 3.1% to settle at $33.55 on Monday. Pfizer shares gained 3.6% to settle at $23.09 on Monday.

Harrow CEO Mark Baum said Harrow is “flourishing,” growing from approximately 140 employees in 2019 to about 175 today, and “$50 million or so in revenue,” a number he said could quadruple ...